Ucb Pharma, S.a.

Other

Ucbbiopharma Srl

Katholieke Universiteit Leuven, Ku Leuven R&d

Ucb Biopharma Sprl

Celltech R&d Limited

Richard Jeremy Franklin

Daniel James Ford

Daniel Christopher Brookings

James Thomas Reuberson

Anant Ramrao Ghawalkar

Rikki Peter Alexander

Judi Charlotte Neuss

Helen Tracey Horsley

Anne Marie Foley

Barry John Langham

Bart Vanderhoydonck

Qiuya Huang

Karen Viviane Lucile Crépy

Pavandeep Singh Aujla

Claire Louise Kulisa

Alan Findlay Haughan

Julien Alistair Brown

Timothy John Norman

Jeremy Martin Davis

Matthew Duncan Selby

Verity Margaret Sabin

Joanna Rachel Quincey

George Martin Buckley

Alistair James Henry

Mezher Hussein Ali

James Madden

William Ross Pitt

Stephen Robert Mack

Oliver Philps

Giancarlo Trani

Rachel Jane Cubbon

Gregory William Haslett

Kerry Jenkins

Manisha Naik

Trevor Morgan

Benjamin Garfield Perry

Andrew Harry Parton

David Jonathan Phillips

Patrick Marie Ghislain Pasau

Bénédicte Irma Léonce Frédérique Lallemand

Pfrafulkumar Tulshibhai Chovatia

Konstantinos Rampalakos

Zhaoning Zhu

Rickki Lee Connelly

Selvaratnam Suganthan

William Mark Jones

Karen Viviane Lucile Crepy

Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

Thiophene derivatives for the treatment of disorders caused by IgE

A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

Therapeutically active pyrazolo-pyrimidine derivatives

Compounds of formula (I) i.e. monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives substituted by an optionally substituted oxazolin-2-yl moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection. 

Therapeutically active oxazoline derivatives

A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection. 

Therapeutically active thiazolo-pyrimidine derivatives

Disclosed are a series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. The compounds are of general formula (I): 

Quinoline derivatives as kinase inhibitors

A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Fused thiazole derivatives as kinase inhibitors

A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Compounds of formula (1) are described in which Rand Ris each independently a hydrogen atom or a group R, or Rand Rtogether form an oxo (&#x2550;O) or thio (&#x2550;S) group; X is a N atom or an optionally substituted CH group: Y is a &#x2014;O&#x2014; or &#x2014;S&#x2014; atom or &#x2014;SO&#x2014; or &#x2014;SO&#x2014; group or an optionally substituted &#x2014;CH&#x2014; or &#x2014;NH&#x2014; group with the proviso that when Rand Rtogether form an oxo (&#x2550;O) or thio (&#x2550;S) group Y is an optionally substituted &#x2014;CH&#x2014; or &#x2014;NH-group; Lis a covalent bond or a linker atom or group; p is zero or the integer 1; Alkis an optionally substituted Caliphatic or Cheteroaliphatic chain; n is zero the integer 1, 2 or 3 with the proviso that when n is zero Y is an optionally substituted &#x2014;CH&#x2014; group; Ar is an optionally substituted Caromatic or Cheteroaromatic group; m is zero or the integer 1, 2 or 3; q is zero or the integer 1 or 2; R, Rand Rare hydrogen atoms or the substituents described in the patent specification; and the salts, solvates, hydrates and N-oxides thereof. The compounds are potent and selective inhibitors of p38 kinase and are useful in the treatment of immune or inflammatory disorders.

Pyridine and pyrimidine derivatives

Growing community of inventors

Slough, United Kingdom

Richard Jeremy Franklin